Piperacillin Sodium (Synonyms: CL 227,193, T-1220) |
| Katalog-Nr.GC16755 |
Piperacillin-Natrium ist ein Breitband-β-Lactam-Antibiotikum.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 59703-84-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Piperacillin Sodium is a broad-spectrum semisynthetic penicillin antibiotic used to treat a variety of infections caused by susceptible bacteria[1]. Piperacillin Sodium exerts its antibacterial action by inhibiting bacterial cell wall synthesis and is effective against a wide range of Gram-positive and Gram-negative bacteria, including some strains that produce β-lactamases[2]. Piperacillin Sodium is often used in combination with other drugs, such as tazobactam, to enhance antibacterial efficacy and broaden the spectrum of activity, better addressing resistant strains[3]. Piperacillin Sodium is commonly used to treat respiratory, urinary, intra-abdominal infections, and skin and soft tissue infections[4].
In vitro, Piperacillin Sodium (2μg/mL) inhibits Staphylococcus aureus with an efficacy rate of up to 93%, and Piperacillin Sodium (4μg/mL) inhibits Escherichia coli with an efficacy rate of up to 90%[5]. Piperacillin Sodium (2–8μg/mL) pre-treatment of various bacteria (Klebsiella pneumoniae, Streptococcus agalactiae, Proteus vulgaris, Haemophilus influenzae) for 18 hours significantly inhibits bacterial growth and reduces resistance[6].
In vivo, Piperacillin Sodium (2.5–5120mg/kg) in combination with the novel β-lactamase inhibitor IID572 (4–640mg/kg) administered subcutaneously three times daily was used in a neutropenic C57BL/6J mouse thigh infection model. The combination of Piperacillin/IID572 significantly reduced the infection burden caused by β-lactamase-producing Enterobacteriaceae and Staphylococcus aureus[7]. Subcutaneous injection of Piperacillin Sodium (10.7mg) in combination with oral β-lactamase (1 or 6mg/kg) was used in CF-1 mice. Compared with mice treated with Piperacillin Sodium alone, the combination with β-lactamase significantly reduced intestinal colonization by Piperacillin-resistant pathogens (including vancomycin-resistant Enterococcus faecium, Klebsiella pneumoniae, and Candida glabrata) and minimized disruption of the indigenous microbiota[8].
References:
[1] Fortner CL, Finley RS, Schimpff SC. Piperacillin sodium: antibacterial spectrum, pharmacokinetics, clinical efficacy, and adverse reactions. Pharmacotherapy. 1982 Nov-Dec;2(6):287-99.
[2] Holmes B, Richards DM, Brogden RN, et al. Piperacillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1984 Nov;28(5):375-425.
[3] Eliopoulos GM, Moellering RC Jr. Azlocillin, mezlocillin, and piperacillin: new broad-spectrum penicillins. Ann Intern Med. 1982 Nov;97(5):755-60.
[4] Russo J Jr, Russo ME. Comparative review of two new wide-spectrum penicillins: mezlocillin and piperacillin. Clin Pharm. 1982 May-Jun;1(3):207-16.
[5] Frank U, Mutter J, Schmidt-Eisenlohr E, et al. Comparative in vitro activity of piperacillin, piperacillin-sulbactam and piperacillin-tazobactam against nosocomial pathogens isolated from intensive care patients. Clin Microbiol Infect. 2003 Nov;9(11):1128-32.
[6] Verbist L. In vitro activity of piperacillin, a new semisynthetic penicillin with an unusually broad spectrum of activity. Antimicrob Agents Chemother. 1978 Mar;13(3):349-57. doi: 10.1128/AAC.13.3.349.
[7] Growcott EJ, Gamboa L, Roth T, et al. Efficacy of piperacillin in combination with novel β-lactamase inhibitor IID572 against β-lactamase-producing strains of Enterobacteriaceae and Staphylococcus aureus in murine neutropenic thigh infection models. J Antimicrob Chemother. 2020 Jun 1;75(6):1530-1536.
[8] Stiefel U, Pultz NJ, Harmoinen J, et al. Oral administration of beta-lactamase preserves colonization resistance of piperacillin-treated mice. J Infect Dis. 2003 Nov 15;188(10):1605-9.
| Cell experiment [1]: | |
Cell lines | Klebsiella pneumoniae, Streptococcus agalactiae, Proteus vulgaris, Haemophilus influenzae |
Preparation Method | The in vitro activity of Piperacillin Sodium was tested against these bacterial strains using agar dilution and broth microdilution methods. The minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) were determined. |
Reaction Conditions | 2–8μg/mL; 24h |
Applications | Piperacillin Sodium was effective against Haemophilus influenzae and Streptococcus agalactiae at 2μg/mL. Piperacillin Sodium was more active than ampicillin against Klebsiella pneumoniae at 8μg/mL. |
| Animal experiment [2]: | |
Animal models | Neutropenic CD-1 mice |
Preparation Method | Mice were rendered neutropenic by intraperitoneal injections of cyclophosphamide (150 and 100mg/kg) on days 4 and 1, respectively. Two hours prior to treatment, bacterial inoculum (105–106CFU) was administered into the left gastrocnemius muscle via intramuscular injection. Subcutaneous treatment with Piperacillin Sodium (2.5–5120mg/kg/day)/IID572 (4–640mg/kg/day) or Piperacillin Sodium (5120mg/kg/day) was initiated every 3 hours for 24 hours. |
Dosage form | 2.5–5120mg/kg/day; s.c. |
Applications | IID572 significantly enhances the in vivo bactericidal effect of Piperacillin Sodium. |
References: | |
| Cas No. | 59703-84-3 | SDF | |
| Überlieferungen | CL 227,193, T-1220 | ||
| Chemical Name | sodium;(2S,5R,6R)-6-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate | ||
| Canonical SMILES | CCN1CCN(C(=O)C1=O)C(=O)NC(C2=CC=CC=C2)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)[O-].[Na+] | ||
| Formula | C23H26N5O7S.Na | M.Wt | 539.54 |
| Löslichkeit | ≥ 18.6mg/mL in DMSO | Storage | Store at 2-8°C, sealed storage, away from moisture |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.8534 mL | 9.2672 mL | 18.5343 mL |
| 5 mM | 370.7 μL | 1.8534 mL | 3.7069 mL |
| 10 mM | 185.3 μL | 926.7 μL | 1.8534 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 22 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *